Investor Moves
News
prnewswire.comIceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investorprnewswire.comJun 17
benzinga.comIceCure Stock Surges After 70% ProSense Install Increasebenzinga.comJun 17
prnewswire.comIceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearanceprnewswire.comJun 17
prnewswire.comIceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Complianceprnewswire.comJun 2
prnewswire.comIceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbookedprnewswire.comMay 19